National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2015 (No. 3) (PB 26 of 2015)

EXPLANATORY STATEMENT

NATIONAL HEALTH ACT 1953

NATIONAL HEALTH (LISTING OF PHARMACEUTICAL BENEFITS) AMENDMENT
INSTRUMENT 2015 (No. 3)

PB 26 of 2015

Purpose

The purpose of this legislative instrument, made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953 (the Act), is to amend the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012) to make changes to the pharmaceutical benefits listed on the Pharmaceutical Benefits Scheme (PBS) and related matters.

PB 71 of 2012 determines the pharmaceutical benefits that are on the PBS through declarations of drugs and medicinal preparations, and determinations of forms, manners of administration and brands.  It also provides for related matters (responsible persons, prescribing circumstances, maximum quantities, numbers of repeats, determined quantity and pack quantity, section 100 only status and prescriber bag only status).

Authority

This Instrument exercises various powers in Part VII of the Act, as set out below:

Pharmaceutical benefits listed on the PBS

Subsection 85(2) provides that the Minister may declare drugs and medicinal preparations to which Part VII applies.  A drug or medicinal preparation for which there is a declaration in force under subsection 85(2) is a ‘listed drug’ (subsection 84(1)).  Subsections 85(3) and 85(5) respectively provide that the Minister may determine the form or forms of a listed drug and the manner of administration of a form of a listed drug.  A listed drug in a determined form with a determined manner of administration for that form is a pharmaceutical item (section 84AB).  The Minister may also determine a brand of a pharmaceutical item (subsection 85(6)).  The Minister may also determine the responsible person for a brand of a pharmaceutical item (subsection 84AF(1)).  Under the provisions of section 84AK the Minister may determine the determined quantity and pack quantity for a brand of a pharmaceutical item.

Prescribing pharmaceutical benefits

Subsection 88(1) provides that a medical practitioner is authorised to prescribe a pharmaceutical benefit.  Section 88 provides that the Minister may determine the pharmaceutical benefits that may be prescribed by different classes of prescribers, including participating dental practitioners (subsection 88(1A)), authorised optometrists (subsection 88(1C)), authorised midwives (subsection 88(1D)) and authorised nurse practitioners (subsection 88(1E)).

Subsection 85(7) provides that the Minister may determine the circumstances in which a prescription may be written for the supply of a pharmaceutical benefit.

Paragraph 85A(2)(a) allows the Minister to determine the maximum quantity or number of units of the pharmaceutical item in a pharmaceutical benefit (or of the pharmaceutical benefit where there is no pharmaceutical item) that may, in one prescription, be directed to be supplied on one occasion.  Paragraph 85A(2)(b) also allows the Minister to determine the maximum number of occasions on which the supply of the pharmaceutical benefit may, in one prescription, be directed to be repeated.  The maximum quantities and repeats may be determined for all purposes or for particular purposes.

Supplying pharmaceutical benefits

Subsection 85(2A) provides that the Minister must declare that a particular listed drug can only be provided under a special arrangement under section 100 if the PBAC has recommended under subsection 101(4AAD) that the drug be made available only under special arrangements under section 100.

Paragraph 85(8)(a) provides that the Minister may determine that a particular pharmaceutical benefit may only be supplied under special arrangements under section 100. 

Paragraph 85(8)(b) provides that the Minister may determine that a particular pharmaceutical benefit may only be supplied under special arrangements under section 100 for one or more of the circumstances determined for that pharmaceutical benefit under subsection 85(7).

Subsection 85(2AA) provides that the Minister must declare that a particular listed drug can only be provided under one or more of the prescriber bag provisions if the PBAC has recommended under subsection 101(4AACA) that the drug be made available only under one or more of the prescriber bag provisions.

Paragraph 85(7A) provides that the Minister may determine that a particular pharmaceutical benefit may only be supplied under one or more of the prescriber bag provisions. 

Variation and revocation

Unless there is an express power to revoke or vary PB 71 of 2012 cited in this Instrument and explanatory statement, subsection 33(3) of the Acts Interpretation Act 1901 is relied upon to revoke or vary PB 71 of 2012.

Subsection 101(4AAA) allows the Minister to, by legislative instrument, revoke or vary a subsection 85(2) declaration in relation to a drug or medicinal preparation.  Advice from the Pharmaceutical Benefits Advisory Committee (PBAC) is required if the effect of the legislative instrument would be that a drug or medicinal preparation would cease to be a listed drug (subsection 101(4AAB)).

Changes to PB 71 of 2012 made by this instrument

Schedule 1 to this instrument provides for additions, deletions and changes to drugs, forms, brands, responsible person codes, maximum quantities, the circumstances for prescribing various pharmaceutical benefits (including authority requirements), determined quantities, pack quantities, section 100 only status and prescriber bag only status.  These changes are summarised, by subject matter, in the Attachment.

Consultation

The involvement of interested parties through the membership of PBAC constitutes a formal and ongoing process of consultation.  PBAC is an independent expert body established by section 100A of the Act which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.  PBAC members are appointed following nomination by prescribed organisations and associations from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions.  Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of PBAC, and that would enable them to contribute meaningfully to the deliberations of PBAC.  When recommending the listing of a medicine on the PBS, PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.

Pharmaceutical companies are consulted throughout the process of the listing of their medicines on the PBS and in relation to changes to those listings.  This includes the company submission to the PBAC and involvement throughout the PBAC process, negotiations or consultation on price, guarantee of supply and agreement to final listing details.

Since the announcement of the PBS Medication Charts for Public and Private Hospitals measure in 2014, the Department of Health has undertaken an extensive consultation process involving all key health stakeholders.  These consultations indicate widespread and strong support for the trial of the PBS Hospital Medication Chart and amendments required to the Regulations and associated legislative instruments to support the measure.  Consulted stakeholders include States and Territories, Australian Private Hospital Association, Society of Hospital Pharmacists of Australia, Pharmaceutical Society of Australia, Pharmacy Guild of Australia, Australian Medical Association, Cancer Voices Australia, Consumers Health Forum of Australia, National Prescribing Service, the ACSQHC, and the National E-Health Transition Authority.  Similarly, the Department of Human Services has received strong support from a range of stakeholders for the implementation of paperless (electronic) claiming of PBS/RPBS medicines.  This includes support for transitional arrangements to ensure stakeholder readiness for the implementation of paperless PBS/RPBS claiming.

General

A provision by provision description of this Instrument is contained in the Attachment.

This Instrument commences on 1 April 2015.

This Instrument is a legislative instrument for the purposes of the Legislative Instruments Act 2003.

ATTACHMENT

PROVISION BY PROVISION DESCRIPTION OF THE NATIONAL HEALTH (LISTING OF PHARMACEUTICAL BENEFITS) AMENDMENT INSTRUMENT 2015 (No. 3)

Section 1 Name of Instrument

This section provides that the Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2015 (No. 3) and may also be cited as PB 26 of 2015.

Section 2 Commencement

This section provides that this Instrument commences on 1 April 2015.

Section 3 Amendment of the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

This section provides that Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).

Schedule 1  Amendments

Items 1 to 3 Section 4
Items 1 to 3 propose amendments to section 4 of the Principal Instrument, the Definitions section, by adding definitions for electronic prescription, paper-based prescription and residential care service.

Item 4   After subsection 11(2)
Item 4 proposes the addition of subsection 11(3) to the Principal Instrument.  This subsection states that a medication chart prescription being used for a person receiving treatment in a residential care service, may not be authorised under sections 11 to 15 of the Principal Instrument, except through a Streamlined Authority Code (a method which is described in section 14 of the Principal Instrument).

Item 5  Subsection 12(1)
Item 5 makes a small number of technical changes to section 12 (Authority required procedures – submission of prescription) by substituting a new subsection 12(1).

The changes reflect some drafting simplifications similar to those used in the Regulation amendments for 1 April 2015, and ensure that all types of methods for obtaining an authority under the Principal Instrument do not exclude a medication chart prescription. It is however recognised that if the only method permitted for a particular medicine is ‘Compliance with Written Authority Procedures’ that in practice it is likely to be cumbersome or impractical to use a medication chart prescription.

Item 6   Subsection 13(1)
Item 6 makes a small number of technical changes to section 13 (Authority required procedures – authorisation) by substituting a new subsection 13(1). The changes to section 13 reflect some drafting simplifications similar to those used in the Regulation amendments for 1 April 2015, and ensure that all types of methods for obtaining an authority under the Principal Instrument do not exclude medication chart prescriptions. Subsection 13(1) deals with a paper-based prescription and the method for obtaining a written authority.

Item 7  After subsection 13(1)
Item 7 makes a small number of technical changes to section 13 (Authority required procedures – authorisation) by inserting new subsections 13(1A) and (1B).

Subsection 13(1A) deals with a medication chart prescription that is not also an electronic prescription and the method to obtain a written authority. The method is essentially the same as the usual method to obtain a written authority for a paper-based prescription, except a copy of the medication chart prescription may be submitted.

Subsection 13(1B) deals with an electronic prescription (including a medication chart prescription that is also an electronic prescription) and the method to obtain a written authority. The method is essentially the same as the method to obtain a written authority for a paper-based prescription, except the prescription may be returned by electronic communication.

Items 8 and 9 Paragraph 13(4)(a) and subparagraph 13(4)(b)(ii)
Items 8 and 9 amend paragraph 13(4)(a) and subparagraph 13(4)(b)(ii). Subsection 13(4) deals with telephone or electronic authorities. The amendments remove an obsolete reference to ‘CEO’, and make the references to the authority approval number more precise.

Items 10 and 11 Subsection 14(2) and paragraphs 14(2)(a) and (b)
Item 10 makes technical changes to section 14 (Streamlined Authority Code).  Subsection 14(2) is amended, and paragraphs 14(2)(a) and (b) are repealed to simplify the drafting.

Items 12 to 169

These items amend Schedule 1 of the Principal Instrument and involve additions, deletions and changes to forms, brands, responsible person codes, maximum quantities, the circumstances for prescribing various pharmaceutical benefits (including authority requirements), determined quantities, pack quantities and section 100 only status.  These changes are summarised below.

SUMMARY OF CHANGES

Listed Drugs Added

Listed Drugs Deleted

Forms Added

Forms Deleted

Brands Added

Brands Deleted

Alteration of Brand Name

Alteration of Responsible Person

Addition of Responsible Person Code

Alteration of Circumstances